🧬 Oncology

Prostate Cancer

Most common cancer in men — often slow-growing and curable when localised.

Overview

Prostate cancer affects 1 in 8 UK men. Most cases are adenocarcinomas arising in the peripheral zone. Many are indolent and never cause harm; a minority are aggressive and life-threatening. Risk stratification (PSA, Gleason/ISUP grade, MRI) guides management from active surveillance to radical treatment.

Symptoms

  • • Often asymptomatic — detected on PSA testing
  • • Lower urinary tract symptoms: hesitancy, weak stream, nocturia (usually benign hyperplasia, sometimes cancer)
  • • Haematuria or haematospermia
  • • Bone pain, weight loss or unexplained fatigue (advanced)

Risk factors

  • • Age >50 (>45 in Black men or with family history)
  • • Black ethnicity (1 in 4 lifetime risk)
  • • First-degree relative with prostate cancer
  • • BRCA2 mutation — earlier onset and more aggressive disease

Causes

  • • Genetic: BRCA2, HOXB13, Lynch syndrome
  • • Androgen-driven proliferation
  • • Age-related epithelial change

🚨 Red flags — seek urgent care

  • • Bone pain, especially spinal — possible metastasis
  • • Lower limb weakness or saddle anaesthesia — spinal cord compression (emergency)
  • • Rapid PSA rise on surveillance

When to seek care

  • • Urinary symptoms over 50, or any haematuria
  • • Family history — discuss baseline PSA from age 45
  • • Symptoms suggestive of bone or cord involvement — urgent same-day assessment

Diagnosis

  • • Age-adjusted PSA + digital rectal examination
  • • Multiparametric MRI of prostate before biopsy
  • • Transperineal targeted + systematic biopsy if MRI Likert ≥3
  • • Staging: bone scan, CT, PSMA-PET for intermediate/high risk
  • • Risk stratification: PSA, ISUP grade group, clinical T stage

Treatment

  • • Active surveillance for low/favourable intermediate-risk disease (PSA, MRI, repeat biopsy)
  • • Radical prostatectomy (open, laparoscopic or robotic)
  • • External beam radiotherapy ± brachytherapy boost; commonly with androgen deprivation
  • • Androgen deprivation therapy (LHRH agonists/antagonists)
  • • Advanced disease: docetaxel, abiraterone, enzalutamide, apalutamide, PARP inhibitors (BRCA), Lu-PSMA radioligand therapy
  • • Bone-protective therapy (zoledronate, denosumab) in metastatic disease

Prevention

  • • No proven primary prevention; healthy weight, exercise and Mediterranean-style diet may help
  • • Discuss informed PSA testing from age 50 (45 if higher risk)

Complications

  • • Urinary incontinence and erectile dysfunction after radical treatment
  • • Radiation cystitis or proctitis
  • • Bone metastases — pathological fracture, hypercalcaemia, cord compression
  • • Androgen deprivation: hot flushes, osteoporosis, cardiometabolic risk

Prognosis

5-year survival ~100% for localised disease; ~50% for metastatic disease and improving with novel hormonal and targeted therapies.

Education & self-care

Prostate cancer is highly treatable when caught early. Knowing your risk and discussing PSA testing matters more than waiting for symptoms.

Frequently asked questions

Should I have a PSA test?

It is an informed choice. Discuss benefits and risks with your GP, especially if you are Black or have a family history.

Will treatment make me incontinent?

Some men have temporary urinary or erectile problems; modern surgery and radiotherapy minimise long-term effects.

Is active surveillance safe?

Yes — for carefully selected low-risk disease, with structured PSA, MRI and biopsy follow-up.

Medically reviewed by Dr. Handel Emery, MD, FRCP (UK) · Last reviewed 2026-06-08